近日，海淀侵入式脑机接口领军企业智冉医疗宣布完成3亿元人民币A+轮融资。本轮融资由中科创星领 投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元生创投、红 杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。 左：高通量可拉伸柔性电极；右：《自然・电子学》官网发布截图 除此之外，智冉医疗还实现了其余关键技术底座的全面突破：其国产神经信号采集芯片仅有硬币大小， 功耗较传统芯片直降75%；深度神经网络解码算法，依托海量神经元脑电数据进行训练，可实现高精度 的实时解码；配套的高效率、高精度智能化电极植入机器人，则打通了高通量侵入式脑机接口技术大规 模临床应用的"最后一公里"。 值得关注的是，这是智冉医疗在半年内完成的第二轮融资，短时间内连续获得资本青睐，充分印证了市 场对其在侵入式脑机接口赛道技术实力与发展潜力的双重认可。据悉，本轮所募资金将主要用于推进大 规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 当前，全球脑机接口产业已进入技术分化与临床转化的关键窗口期，侵入式、半侵入式、非侵入式三大 技术路线呈现差异化竞争格局。其中，侵入式路线凭借神经信号采集 ...

近日，国内侵入式脑机接口领军企业智冉医疗宣布完成3亿元人民币A+轮融资。本轮融资由中科创星领 投，老股东君联资本、北京市医药健康产业投资基金、IDG资本、顺为资本、联想创投、元生创投、红 杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投。 值得关注的是，这是智冉医疗在半年内完成的第二轮融资，短时间内连续获得资本青睐，充分印证了市 场对其在侵入式脑机接口赛道技术实力与发展潜力的双重认可。据悉，本轮所募资金将主要用于推进大 规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 从创立之初，智冉就坚定地走侵入式脑机接口技术路线，一方面是因为团队在侵入式脑机接口底层技术 拥有深厚的技术积累；另一方面，是基于对行业终局的深刻认知。脑机接口的未来是要实现人类大脑与 外部设备之间高带宽的信息交互，从而将脑机接口从一种'弥补缺陷'的辅助工具，进化为人类通往高效 人机共生的核心底层技术，而只有侵入式脑机接口的路线能够实现这一跨越。 当前，植入式脑机接口已然形成了两种技术路线：半侵入式脑机接口和侵入式脑机接口。两者的本质区 别在于电极与脑组织的物理位置关系，这直接决定了神经信号的质量与应用上限。半侵入式 ...

Core Viewpoint - The article discusses the recent advancements and funding in the invasive brain-computer interface (BCI) sector, particularly focusing on the company "Zhiran Medical," which has completed a 300 million RMB A+ round of financing to enhance clinical trials and product iterations [2]. Group 1: Company Overview - Zhiran Medical has established a systematic layout in the upstream and midstream of the invasive BCI industry chain, focusing on core technology development and large-scale production [3][6]. - The company has made significant breakthroughs in key technologies, including flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots, creating a complete industrial closed loop [3][6]. Group 2: Technological Advancements - Zhiran Medical's recent innovation includes a stretchable high-throughput flexible electrode that addresses issues of traditional linear electrodes, enhancing signal collection and biomechanical compliance [4][6]. - The company's neural signal acquisition chip is coin-sized and has reduced power consumption by 75% compared to traditional chips, while the deep neural network decoding algorithm allows for high-precision real-time decoding [6]. Group 3: Clinical Applications - By 2025, Zhiran Medical successfully completed the clinical implantation of the first domestic invasive BCI product with over 100 channels, validating its safety and effectiveness [6]. - The company plans to initiate large-scale clinical registration for its over 100-channel invasive BCI product in 2026, accelerating its clinical application [6]. Group 4: Industry Positioning - As a leading innovator in the domestic invasive BCI field, Zhiran Medical aligns with China's "14th Five-Year Plan" for future industry development and responds to national calls for independent innovation in cutting-edge technologies [7].

近日，国内侵入式脑机接口领军企业智冉医疗完成3亿元A+轮融资，本轮融资由中科创星领投，老股东君联资本、北京市医药健康产业投资基金、IDG资 本、顺为资本、联想创投、元生创投、红杉中国、美团龙珠、BV百度风投、杏泽资本、佳银资本持续跟投，这也是智冉医疗在半年内完成的第二轮融资 据了解，本轮融资将主要用于推进大规模临床试验与高通量柔性脑机接口产品迭代，加速该技术向临床应用落地。 来源：猎云网 从创立之初，智冉就坚定地走侵入式脑机接口技术路线，一方面是因为团队在侵入式脑机接口底层技术拥有深厚的技术积累；另一方面，是基于对行业终局 的深刻认知。脑机接口的未来是要实现人类大脑与外部设备之间高带宽的信息交互，从而将脑机接口从一种'弥补缺陷'的辅助工具，进化为人类通往高效人 机共生的核心底层技术，而只有侵入式脑机接口的路线能够实现这一跨越。 当前，植入式脑机接口已然形成了两种技术路线：半侵入式脑机接口和侵入式脑机接口。两者的本质区别在于电极与脑组织的物理位置关系，这直接决定了 神经信号的质量与应用上限。半侵入式脑机接口通过将电极放置在硬膜上或者硬膜下采集大脑中的神经信号，由于神经信号随着传输距离迅速衰减，半侵入 式脑机接口 ...

本轮融资主要用于推进大规模临床试验、高通量柔性脑机接口产品迭代，加速侵入式脑机接口技术的临 床应用落地。 可拉伸柔性电极植入大脑后的动态运动效果，企业供图 除了攻克柔性电极的难点，成立至今，智冉医疗在神经芯片、解码算法与电极植入机器人方面，也已经 完成研发布局。另外，自建了近2000㎡临床级微纳加工车间与GMP标准组装车间，实现临床级产品的 全链条自主可控。 去年8月，智冉医疗刚获得超3亿元A轮融资。时隔半年再次拿到大额融资，且老股东集体加注，可见投 资机构对智冉医疗侵入式脑机接口全栈能力的认可。 智冉医疗创始人、CEO宋麒告诉36氪，从创立之初，智冉就坚定做侵入式脑机接口，一方面是因为团队 在侵入式脑机接口底层技术拥有深厚的技术积累；另一方面，脑机接口的未来终局不会限于瘫痪患者脑 控外设、功能重建等，而要实现高效的人机信息互通，只有侵入式脑机接口能够做到真正高通量、高质 量的信号读写。 "柔性电极"这一核心部件，可谓是侵入式脑机接口赛道的关键入场券。人的大脑是非常柔软的组织，电 极植入大脑皮层后，如何确保长期不移位，并减少因免疫反应产生瘢痕、而导致脑电信号衰减等，成为 重要研发方向。 智冉医疗创始人方英在柔 ...

去年8月，智冉医疗刚获得超3亿元A轮融资。时隔半年再次拿到大额融资，且老股东集体加注，可见投资机构对智冉医疗侵入式 脑机接口全栈能力的认可。 智冉医疗创始人、CEO宋麒告诉36氪，从创立之初，智冉就坚定做侵入式脑机接口，一方面是因为团队在侵入式脑机接口底层技 术拥有深厚的技术积累；另一方面，脑机接口的未来终局不会限于瘫痪患者脑控外设、功能重建等，而要实现高效的人机信息互 通，只有侵入式脑机接口能够做到真正高通量、高质量的信号读写。 "柔性电极"这一核心部件，可谓是侵入式脑机接口赛道的关键入场券。人的大脑是非常柔软的组织，电极植入大脑皮层后，如何 确保长期不移位，并减少因免疫反应产生瘢痕、而导致脑电信号衰减等，成为重要研发方向。 智冉医疗创始人方英在柔性高通量电极与神经记录调控研究领域深耕多年，有多项突破性成果。研发的高通量"可拉伸柔性电 极"在植入大脑后，能够动态跟随大脑的搏动与颅内位移，确保了电极在脑组织中的长期稳定性。而且，相比于传统线性电极， 这款可拉伸电极在脑内也更加"柔软"，对脑组织的机械损伤更低。当前，智冉医疗已经研制出基于可拉伸柔性电极的高通量无线 侵入式脑机接口系统。 时 隔半年再次拿到大额融 ...

智通财经获悉，脑机概念股集体高开，截至发稿，脑洞极光(06681)涨10.35%，报6.29港元；南京熊猫电 子股份(00553)涨1.63%，报4.36港元。 中信建投认为，脑机接口产业链上中游的技术进步带来下游应用端不断突破，近年来国内外在运动恢 复、语言沟通、听力重建等医疗领域的研究不断出现里程碑式成果。国家层面和各地区推出多项政策利 好行业加速发展，近期国家医保局发文为脑机接口新技术价格单独立项，其进入临床应用的服务收费路 径已经铺好。在技术革新和政策红利催化下，国内脑机接口公司有望逐步实现商业化应用。 本文源自：智通财经网 消息面上，据证券时报报道，中国科学院脑科学与智能技术卓越创新中心赵郑拓、李雪研究团队今年已 联合相关医院和企业，完成三例侵入式脑机接口临床试验，在生活场景应用方面实现突破。其中，在第 二例临床试验中，研究团队采用高通量无线侵入式脑机接口系统，使一位高位截瘫患者能够通过脑电信 号稳定操控智能轮椅与机器狗，在真实生活场景中实现自主移动与物品取用。 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-computer concept stocks opened high, with notable increases such as Brainhole Aurora (06681) rising by 10.35% to HKD 6.29 and Nanjing Panda Electronics (600775) increasing by 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BCI clinical trials in collaboration with hospitals and enterprises, achieving breakthroughs in real-life applications [1] Clinical Trial Highlights - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for autonomous movement and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the midstream of the BCI industry are leading to breakthroughs in downstream applications, with significant milestones in medical fields such as motor recovery, communication, and hearing restoration [1] - National and regional policies are being introduced to accelerate industry development, including a recent announcement from the National Healthcare Security Administration to establish a separate pricing item for new BCI technologies, paving the way for clinical application service charges [1] - With technological innovations and policy support, domestic BCI companies are expected to gradually achieve commercialization [1]

Core Viewpoint - The brain-machine interface (BMI) sector is experiencing significant advancements, with recent clinical trials demonstrating practical applications that could lead to commercial opportunities in the healthcare industry [1] Industry Developments - The brain-machine concept stocks opened high, with notable increases in share prices: Brainhole Aurora (06681) up 10.35% to HKD 6.29 and Nanjing Panda Electronics (00553) up 1.63% to HKD 4.36 [1] - A research team from the Chinese Academy of Sciences has completed three invasive BMI clinical trials, achieving breakthroughs in real-life applications [1] Clinical Trial Achievements - In the second clinical trial, a high-level paraplegic patient was able to control a smart wheelchair and robotic dog using brain signals, demonstrating the potential for independent mobility and object retrieval in real-life scenarios [1] Market Outlook - CITIC Securities believes that technological advancements in the upstream BMI industry are leading to breakthroughs in downstream applications, particularly in rehabilitation, communication, and hearing restoration [1] - The Chinese government and various regions are implementing policies to accelerate the industry's development, including the National Healthcare Security Administration's recent decision to separately list pricing for new BMI technologies [1] - With technological innovations and policy support, domestic BMI companies are expected to gradually achieve commercial applications [1]

Group 1: Event Overview - The 11th China (Shanghai) International Technology Import and Export Fair was held from June 11 to June 13, focusing on "hard technology" and future industries, showcasing nearly a hundred breakthrough achievements in fields like brain-machine interfaces, embodied intelligence, quantum technology, and synthetic biology [1][2] - The event highlighted significant innovations such as the world's first sound tweezers single-cell sorting technology and the debut of self-developed lunar soil fiber technology and equipment, indicating a promising future for the technology industry [1][2] Group 2: Innovations in Lunar Technology - East China University of Science and Technology showcased the "in-situ preparation of lunar soil fiber modular equipment," which is included in China's lunar base construction plan, utilizing lunar soil from the Chang'e 5 mission to create fibers for lunar base construction [2] - The technology aims to convert lunar soil into high-performance fibers, enabling local resource utilization and meeting the material performance needs for lunar base construction [2] Group 3: Advancements in Biotechnology - The Soundpen CB system developed by Oubino Biotechnology employs non-contact, label-free acoustic tweezers to manipulate cells with precision, significantly enhancing experimental efficiency by minimizing cell damage [3] - The event also featured brain-machine interface technologies that allow patients with central nervous system injuries to control exoskeletons for rehabilitation, demonstrating practical applications in hospitals and rehabilitation centers [5][6] Group 4: Robotics and Automation - The fair showcased various robots, including a six-legged robot designed for Antarctic research, which can assist in transporting materials and ensuring safety by detecting cracks in the ice [3][4] - Nanjing University presented a multimodal interactive robot capable of intelligent dialogue and music synchronization, which is already in mass production and available in North America [4] Group 5: 3D Printing in Pharmaceuticals - The company San Diego demonstrated its 3D printing technology for pharmaceuticals, achieving continuous and large-scale production of printed drugs, with an annual capacity of 75 million to 300 million tablets [6] - Lepu Medical introduced the MemoSorb biodegradable occluder series, the first of its kind globally, providing innovative treatment solutions for congenital heart disease and stroke prevention [6]